These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 1333270)

  • 1. Soluble CD8, CD25 and CD30 antigens as prognostic markers in patients with untreated Hodgkin's lymphoma.
    Gause A; Jung W; Schmits R; Tschiersch A; Scholz R; Pohl C; Hasenclever D; Diehl V; Pfreundschuh M
    Ann Oncol; 1992 Sep; 3 Suppl 4():49-52. PubMed ID: 1333270
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical significance of soluble CD30 antigen in the sera of patients with untreated Hodgkin's disease.
    Gause A; Pohl C; Tschiersch A; Da Costa L; Jung W; Diehl V; Hasenclever D; Pfreundschuh M
    Blood; 1991 May; 77(9):1983-8. PubMed ID: 1850308
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Soluble molecules as biological markers in Hodgkin's disease.
    Nadali G; Vinante F; Chilosi M; Pizzolo G
    Leuk Lymphoma; 1997 Dec; 26 Suppl 1():99-105. PubMed ID: 9570686
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The clinical significance of serum CD8 antigen levels in adult patients with Hodgkin's disease.
    Gause A; Verpoort K; Roschansky V; Tschiersch A; Hasenclever D; Schmits R; Diehl V; Brosteanu O; Pfreundschuh M
    Ann Oncol; 1991 Sep; 2(8):579-83. PubMed ID: 1724380
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biological markers may add to prediction of outcome achieved by the International Prognostic Score in Hodgkin's disease.
    Axdorph U; Sjöberg J; Grimfors G; Landgren O; Porwit-MacDonald A; Björkholm M
    Ann Oncol; 2000 Nov; 11(11):1405-11. PubMed ID: 11142480
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Soluble ICAM-1 in Hodgkin's disease: a promising independent predictive marker for survival.
    Christiansen I; Enblad G; Kälkner KM; Gidlöf C; Glimelius B; Tötterman TH
    Leuk Lymphoma; 1995 Oct; 19(3-4):243-51. PubMed ID: 8535215
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Soluble interleukin-2 receptor and soluble CD8 antigen levels in serum from patients with solid tumors.
    Orditura M; De Vita F; Roscigno A; Auriemma A; Infusino S; Catalano G
    Int J Mol Med; 1998 Jul; 2(1):75-9. PubMed ID: 9854147
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Soluble interleukin-2 receptor, soluble CD8 and soluble intercellular adhesion molecule-1 levels in hematologic malignancies.
    Srivastava MD; Srivastava A; Srivastava BI
    Leuk Lymphoma; 1994 Jan; 12(3-4):241-51. PubMed ID: 7909467
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical significance of serial measurement of the serum levels of soluble interleukin-2 receptor and soluble CD8 in malignant lymphoma.
    Motokura T; Kobayashi Y; Fujita A; Nakamura Y; Taniguchi T; Uchimaru K; Asano S
    Leuk Lymphoma; 1995 Jan; 16(3-4):355-62. PubMed ID: 7719243
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum levels of soluble CD30 are elevated in the majority of untreated patients with Hodgkin's disease and correlate with clinical features and prognosis.
    Nadali G; Vinante F; Ambrosetti A; Todeschini G; Veneri D; Zanotti R; Meneghini V; Ricetti MM; Benedetti F; Vassanelli A
    J Clin Oncol; 1994 Apr; 12(4):793-7. PubMed ID: 8151321
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The clinical significance of cytokines and soluble forms of membrane-derived activation antigens in the serum of patients with Hodgkin's disease.
    Gause A; Jung W; Keymis S; Schobert I; Scholz R; Schmits R; Diehl V; Pohl C; Hasenclever D; Pfreundschuh M
    Leuk Lymphoma; 1992 Aug; 7(5-6):439-47. PubMed ID: 1283546
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Increased serum CD8 soluble antigen level is associated with blood lymphocyte abnormalities and other established indicators of a poor prognosis in adult Hodgkin's disease.
    Grimfors G; Andersson B; Tullgren O; Giscombe R; Holm G; Johansson B; Björkholm M
    Br J Haematol; 1992 Feb; 80(2):166-71. PubMed ID: 1550771
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum levels of soluble CD30 molecule (Ki-1 antigen) in Hodgkin's disease: relationship with disease activity and clinical stage.
    Pizzolo G; Vinante F; Chilosi M; Dallenbach F; Josimovic-Alasevic O; Diamantstein T; Stein H
    Br J Haematol; 1990 Jun; 75(2):282-4. PubMed ID: 2164839
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tumor burden and serum level of soluble CD25, CD8, CD23, CD54 and CD44 in non-Hodgkin's lymphoma.
    Pérez-Encinas M; Villamayor M; Campos A; González S; Bello JL
    Haematologica; 1998 Aug; 83(8):752-4. PubMed ID: 9793264
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serum level of the soluble form of the CD30 molecule identifies patients with Hodgkin's disease at high risk of unfavorable outcome.
    Nadali G; Tavecchia L; Zanolin E; Bonfante V; Viviani S; Camerini E; Musto P; Di Renzo N; Carotenuto M; Chilosi M; Krampera M; Pizzolo G
    Blood; 1998 Apr; 91(8):3011-6. PubMed ID: 9531614
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Differential diagnostic and prognostic value of serum cytokines (soluble CD30, soluble interleukin-2 receptor, interleukin-10 and interleukin-6) in Hodgkin's disease and lymphosarcomas].
    Iaguzhinskaia OE; Lazarev IE; Nikitin EA; Samoĭlova RS; Loginova IV; Gemdzhan EG; Novikov VA; Mamiliaeva ZKh; Pivnik AV
    Ter Arkh; 2001; 73(4):45-51. PubMed ID: 11494447
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical implications of serum levels of soluble CD30 in 70 adult anaplastic large-cell lymphoma patients.
    Zinzani PL; Pileri S; Bendandi M; Buzzi M; Sabattini E; Ascani S; Gherlinzoni F; Magagnoli M; Albertini P; Tura S
    J Clin Oncol; 1998 Apr; 16(4):1532-7. PubMed ID: 9552063
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Very high levels of soluble CD30 recognize the patients with classical Hodgkin's lymphoma retaining a very poor prognosis.
    Visco C; Nadali G; Vassilakopoulos TP; Bonfante V; Viviani S; Gianni AM; Federico M; Luminari S; Peethambaram P; Witzig TE; Pangalis G; Cabanillas F; Medeiros LJ; Sarris AH; Pizzolo G
    Eur J Haematol; 2006 Nov; 77(5):387-94. PubMed ID: 16879607
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Circulating CD20 and CD52 in patients with non-Hodgkin's lymphoma or Hodgkin's disease.
    Giles FJ; Vose JM; Do KA; Johnson MM; Manshouri T; Bociek G; Bierman PJ; O'Brien SM; Keating MJ; Kantarjian HM; Armitage JO; Albitar M
    Br J Haematol; 2003 Dec; 123(5):850-7. PubMed ID: 14632776
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Epstein-Barr virus expression in Hodgkin's disease in relation to patient characteristics, serum factors and blood lymphocyte function.
    Axdorph U; Porwit-MacDonald A; Sjöberg J; Grimfors G; Ekman M; Wang W; Biberfeld P; Björkholm M
    Br J Cancer; 1999 Dec; 81(7):1182-7. PubMed ID: 10584880
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.